Concert Pharmaceuticals Inc. (CNCE) Sets New 52-Week Low at $9.64
Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reached a new 52-week low on Monday . The stock traded as low as $9.64 and last traded at $9.66, with a volume of 113,499 shares traded. The stock had previously closed at $10.14.
CNCE has been the topic of several research reports. Zacks Investment Research upgraded shares of Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Brean Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Concert Pharmaceuticals in a research note on Friday, May 6th. Finally, Stifel Nicolaus initiated coverage on shares of Concert Pharmaceuticals in a research note on Friday, July 1st. They set a “buy” rating and a $23.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. Concert Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $26.43.
The company’s 50 day moving average is $11.38 and its 200 day moving average is $12.48. The stock’s market cap is $214.71 million.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its earnings results on Tuesday, August 9th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.03. Equities research analysts forecast that Concert Pharmaceuticals Inc. will post ($2.51) EPS for the current fiscal year.
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.